| 产品名称： | BDCM |
|---|---|
| 商品货号： | TS139054 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | B lymphoblast |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 xa0Cells contain EBV viral DNA sequences
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute myelogenous leukemia (AML) |
| Age： | unknown |
| Gender： | male |
| Ethnicity： | unknown |
| Applications： | Cells may be useful in modeling immune reactions. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | BDCM is a B cell line established from a pheresis sample from a patient with M5a leukemia. |
| Clinical Data： | male
unknown |
| Antigen Expression： | CD20; Homo sapiens, expressed
CD19; Homo sapiens, expressed
CD40; Homo sapiens, expressed
CD80; Homo sapiens, expressed
CD83; Homo sapiens, expressed
CD86; Homo sapiens, expressed
HLA-DR; Homo sapiens, expressed
CD1a; Homo sapiens, not expressed
CD11c; Homo sapiens, not expressed |
| Receptor Expression： | interleukin 3 (IL-3) |
| Comments： | In addition to B cell markers, the cells have many characteristics of dendritic cells. The cells are positive for Epstein-barr virus (EBV). They produce fascin, interleukin 1 alpha (IL-1 alpha), interleukin 2 (IL-2), interleukin 6 (IL-6), interleukin 16 (IL-16), transforming growth factor beta1 (TGF beta1), and tumor necrosis factor (TNF). xa0 |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 X 105 cells/mL and maintain between 3 X 105 and 3 X 106 cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 10,11 D13S317: 11 D16S539: 10,11 D5S818: 12,13 D7S820: 9,11 THO1: 6,9.3 TPOX: 9,10 vWA: 16,17 |
| Name of Depositor： | RA Steinman |
| Deposited As： | human |
| References： | Kharbanda S, et al. BDCM: a novel B-cell line with genetic and functional similarity to dendritic cells. Br. J. Haematol. 119: 819-825, 2002. PubMed: 12437665 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | BDCM |
|---|---|
| 商品货号： | TS139054 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | B lymphoblast |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 xa0Cells contain EBV viral DNA sequences
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute myelogenous leukemia (AML) |
| Age： | unknown |
| Gender： | male |
| Ethnicity： | unknown |
| Applications： | Cells may be useful in modeling immune reactions. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | BDCM is a B cell line established from a pheresis sample from a patient with M5a leukemia. |
| Clinical Data： | male
unknown |
| Antigen Expression： | CD20; Homo sapiens, expressed
CD19; Homo sapiens, expressed
CD40; Homo sapiens, expressed
CD80; Homo sapiens, expressed
CD83; Homo sapiens, expressed
CD86; Homo sapiens, expressed
HLA-DR; Homo sapiens, expressed
CD1a; Homo sapiens, not expressed
CD11c; Homo sapiens, not expressed |
| Receptor Expression： | interleukin 3 (IL-3) |
| Comments： | In addition to B cell markers, the cells have many characteristics of dendritic cells. The cells are positive for Epstein-barr virus (EBV). They produce fascin, interleukin 1 alpha (IL-1 alpha), interleukin 2 (IL-2), interleukin 6 (IL-6), interleukin 16 (IL-16), transforming growth factor beta1 (TGF beta1), and tumor necrosis factor (TNF). xa0 |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 X 105 cells/mL and maintain between 3 X 105 and 3 X 106 cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 10,11 D13S317: 11 D16S539: 10,11 D5S818: 12,13 D7S820: 9,11 THO1: 6,9.3 TPOX: 9,10 vWA: 16,17 |
| Name of Depositor： | RA Steinman |
| Deposited As： | human |
| References： | Kharbanda S, et al. BDCM: a novel B-cell line with genetic and functional similarity to dendritic cells. Br. J. Haematol. 119: 819-825, 2002. PubMed: 12437665 |
